Hutchison China Meditech Share Price (HCM)

4,610.00 -55.00 (-1.18%) delayed: 9:31PM GMT
Bid price 4,570.00 Open price 4,665.00
Ask price 4,650.00 Prev close 4,610.00
High price 4,699.30 Spread 1.72%
Low price 4,570.00 Volume 8,675

Register now for FREE live Hutchison China Meditech share prices, Hutchison China Meditech stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Hutchison China Meditech Level 2 Data, indepth research tools and investor commentary for Hutchison China Meditech (HCM) and other London Stock Exchange equities.

Hutchison China Meditech Share Price Chart

Advanced Charts >>

Register now for FREE Hutchison China Meditech share price charts

Hutchison China Meditech Share Price Information

Name Hutchison China Meditech Epic HCM
Sector Pharmaceuticals & Biotechnology ISIN KYG4672N1016
Activites Hutchison China MediTech Limited (Chi-Med) is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited. Index n/a

Hutchison China Meditech Key Numbers

Latest Share Price (p) 4,610.00 Net Gearing (%) 17.21
Market Capitalisation (£m) 3,020.02 Gross Gearing (%) 40.41
Shares in issue (m) 66.45 Debt Ratio 17.49
P/E Ratio 227.25 Debt-to-Equity Ratio 0.31
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.68
Dividend Yield (%) 0.00 Price to book value 14.80
Dividend cover (x) 0.00 ROCE (%) 5.89
Earning per share (p) 20.00 EPS Growth (%) 131.25
52 week high / low 5,890.00 / 2,085.00 DPS Growth (%) n/a

Hutchison China Meditech Director Deals

Dec.Date Type Director Pos No. of Shares
07/08/2017 BUY Dr Dan Eldar NED 1,900
07/08/2017 BUY Paul Carter NED 724
29/03/2017 TIN Christian Hogg CEO 5,620
20/03/2017 BUY Paul Carter NED 2,800
23/11/2016 SELL Michael Howell RES 10,000

More Hutchison China Meditech Director Deals >>

Hutchison China Meditech Company News

09:41 13/02/2018

Hutchison China MediTech completes patient enrollment of Faluca

Hutchison China MediTech Limited said it completed the enrollment of 527 patients in pivotal phase III faluca trial with fruquintinib in lung cancer. Top-line Faluca data is expected to be reported in late 2018. If the data is positive, then the company said it would plan a second new drug...

07:01 13/02/2018

Enrolment completed Ph III FALUCA Fruquintinib

RNS Number : 7097E Hutchison China Meditech Limited 13 February 2018   Press Release    Chi-Med Completes Enrollment of 527 Patients in Pivotal Phase III FALUCA Trial with Fruquintinib in Lung Cancer London : Tuesday, February 13, 2018 : Hutchison China MediTech...

07:00 05/02/2018

Chi-Med to Announce 2017 Final Results

RNS Number : 7593D Hutchison China Meditech Limited 05 February 2018   Chi-Med to Announce 2017 Final Results   London: Monday , February 5, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) will be announcing its final results for the year...

More Hutchison China Meditech Company News >>

Register now for FREE Hutchison China Meditech company news

Hutchison China Meditech Share Price Discussions

5 days ago

Hutchison China Meditech (HCM)

Hutchison China MediTech Limited ("Chi-Med") is a China-based globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in...

Register now for FREE Hutchison China Meditech share price discussions